Health Care·Biotechnology·$11.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.35 | N/A | +372.97% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.35 | N/A | +372.97% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to pipeline development. However, they did not provide specific guidance for the future.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline and maximizing shareholder value.
Exelixis Inc reported a strong EPS performance, significantly exceeding expectations, which reflects effective cost management and operational efficiency. However, the stock fell by 3.88% following the earnings report, indicating investor concerns or profit-taking despite the positive EPS surprise. The lack of revenue data and forward guidance may have contributed to the stock's decline.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MEDPACE HLDGS INC
Feb 14, 2022